SLC5A2 and chronic kidney disease: In addition, long-term effects have been previously demonstrated in patients with albuminuric CKD (A3, >300 mg/g) without T2D, where treatment with SGLT2 inhibitors in addition to standard therapy were found to avoid progression to kidney failure [17].